Clinical Trial Update: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing CXA-201 versus levofloxacin in complicated urinary tract infection with pyelonephritis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Urinary Tract Infection
• Pyelonephritis

Drugs mentioned

• CXA-201
• Levofloxacin (Levofloxacin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Complicated Urinary Tract Infection, Pyelonephritis | Phase 3 | Status: COMPLETED | Results posted: 2015-01-15